Nasal potential difference measurements in patients with atypical cystic fibrosis

被引:80
作者
Wilschanski, M
Famini, H
Strauss-Liviatan, N
Rivlin, J
Blau, H
Bibi, H
Bentur, L
Yahav, Y
Springer, H
Kramer, MR
Klar, A
Ilani, A
Kerem, B
Kerem, E
机构
[1] Hadassah Hosp, Informat Syst Div, Jerusalem, Israel
[2] Carmel Med Ctr, Cyst Fibrosis Ctr, Haifa, Israel
[3] Schneider Childrens Hosp, Graub Cyst Fibrosis Ctr, Petach Tiqva, Israel
[4] Barzilai Med Ctr, Pediat Pulm Unit, Ashkelon, Israel
[5] Rambam Med Ctr, Cyst Fibrosis Ctr, Haifa, Israel
[6] Chaim Sheba Med Ctr, Cyst Fibrosis Ctr, IL-52621 Tel Hashomer, Israel
[7] Hadassah Univ Hosp, Pulm Inst, IL-91120 Jerusalem, Israel
[8] Rabin Med Ctr, Pulm Inst, Petach Tiqva, Israel
[9] Bikur Cholim Hosp, Dept Pediat, Jerusalem, Israel
[10] Hebrew Univ Jerusalem, Dept Neurophysiol, Jerusalem, Israel
[11] Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, Jerusalem, Israel
[12] Hebrew Univ Jerusalem, Sch Med, Shaare Zedek Med Ctr, Dept Pediat,Cyst Fibrosis Ctr, IL-91031 Jerusalem, Israel
关键词
atypical phenotype; cystic fibrosis; genotype-phenotype; nasal potential difference;
D O I
10.1183/09031936.01.00092501
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The diagnosis of cystic fibrosis (CF) is based on characteristic clinical and laboratory findings. However, a subgroup of patients present with an atypical phenotype that comprises partial CF phenotype, borderline sn eat tests and one or even no common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. The aim of this study was to evaluate the role of nasal potential difference (PD) measurements in the diagnosis of CF patients with an atypical presentation and in a population of patients suspected to have CF, Nasal PD was measured in 162 patients from four different groups: patients with classical CF (n = 31), atypical phenotype (n = it), controls (n = 50), and patients with questionable CF (n = 70), The parameter, or combination of nasal PD parameters was calculated in order to best discriminate all CF patients (including atypical CF) from the non-CF group. The patients with atypical CF disease had intermediate values of PD measurements between the CF and non-CF groups. The best discriminate model that assigned all atypical CF patients as CF used: e((response to chloride-free and isoproterenol/response to amiloride)) with a cut-off >0.70 to predict a CF diagnosis. When this model was applied to the group of 70 patients,with questionable CF, 24 patients had abnormal PD similar to the atypical CF group. These patients had higher levels of sweat chloride concentration and increased rate of CFTR mutations. Nasal potential difference is useful in diagnosis of patients with atypical cystic fibrosis, Taking into account both the sodium and chloride transport elements of the potential difference allows for better differentiation between atypical cystic fibrosis and noncystic fibrosis patients. This calculation may assist in the diagnostic work-up of patients whose diagnosis is questionable.
引用
收藏
页码:1208 / 1215
页数:8
相关论文
共 45 条
[1]  
ABELIOVICH D, 1992, AM J HUM GENET, V51, P951
[2]   Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis:: a double-blind placebo-controlled trial [J].
Alton, EWFW ;
Stern, M ;
Farley, R ;
Jaffe, A ;
Chadwick, SL ;
Phillips, J ;
Davies, J ;
Smith, SN ;
Browning, J ;
Davies, MG ;
Hodson, ME ;
Durham, SR ;
Li, D ;
Jeffery, PK ;
Scallan, M ;
Balfour, R ;
Eastman, SJ ;
Cheng, SH ;
Smith, AE ;
Meeker, D ;
Geddes, DM .
LANCET, 1999, 353 (9157) :947-954
[3]   Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX) [J].
Arispe, N ;
Ma, JJ ;
Jacobson, KA ;
Pollard, HB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (10) :5727-5734
[4]   MILD CYSTIC-FIBROSIS AND NORMAL OR BORDERLINE SWEAT TEST IN PATIENTS WITH THE 3849+10 KB C-]T MUTATION [J].
AUGARTEN, A ;
KEREM, BS ;
YAHAV, Y ;
NOIMAN, S ;
RIVLIN, Y ;
TAL, A ;
BLAU, H ;
BENTUR, L ;
SZEINBERG, A ;
KEREM, E ;
GAZIT, E .
LANCET, 1993, 342 (8862) :25-26
[5]   GENETIC INFLUENCES IN THE FORMATION OF NASAL POLYPS [J].
BURGER, J ;
MACEK, M ;
STUHRMANN, M ;
REIS, A ;
KRAWCZAK, M ;
SCHMIDTKE, J .
LANCET, 1991, 337 (8747) :974-974
[6]   MUTATIONS IN THE CYSTIC-FIBROSIS GENE IN PATIENTS WITH CONGENITAL ABSENCE OF THE VAS-DEFERENS [J].
CHILLON, M ;
CASALS, T ;
MERCIER, B ;
BASSAS, L ;
LISSENS, W ;
SILBER, S ;
ROMEY, MC ;
RUIZROMERO, J ;
VERLINGUE, C ;
CLAUSTRES, M ;
NUNES, V ;
FEREC, C ;
ESTIVILL, X .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (22) :1475-1480
[7]   Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis [J].
Cohn, JA ;
Friedman, KJ ;
Noone, PG ;
Knowles, MR ;
Silverman, LM ;
Jowell, PS .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (10) :653-658
[8]   ΔF508 heterozygosity in cystic fibrosis and susceptibility to asthma [J].
Dahl, M ;
Tybjærg-Hansen, A ;
Lange, P ;
Nordestgaard, BG .
LANCET, 1998, 351 (9120) :1911-1913
[9]  
Danner I, 1999, EUR RESPIR J, V13, P1276, DOI 10.1183/09031936.99.13612819
[10]  
DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P8